VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q2 2023. The put-call ratio across all filers is 4.14 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $402,296,129 | +2.1% | 7,891,254 | 0.0% | 7.92% | +6.4% |
Q2 2023 | $394,089,225 | +44.2% | 7,891,254 | +8.2% | 7.44% | +20.3% |
Q1 2023 | $273,276,200 | -2.7% | 7,291,254 | +24.5% | 6.19% | +8.6% |
Q4 2022 | $280,865,159 | +155.5% | 5,857,459 | +27.9% | 5.70% | +142.8% |
Q3 2022 | $109,949,000 | +10.3% | 4,581,203 | 0.0% | 2.35% | -11.7% |
Q2 2022 | $99,687,000 | -9.9% | 4,581,203 | 0.0% | 2.66% | +10.1% |
Q1 2022 | $110,636,000 | +9.7% | 4,581,203 | +8.0% | 2.41% | +35.7% |
Q4 2021 | $100,881,000 | +2.0% | 4,240,464 | +8.8% | 1.78% | +29.9% |
Q3 2021 | $98,863,000 | +13.6% | 3,896,865 | +0.8% | 1.37% | -1.9% |
Q2 2021 | $87,019,000 | +14.0% | 3,865,808 | 0.0% | 1.40% | +21.4% |
Q1 2021 | $76,350,000 | -22.6% | 3,865,808 | +4.2% | 1.15% | -16.5% |
Q4 2020 | $98,593,000 | -62.2% | 3,710,699 | -29.8% | 1.38% | -71.1% |
Q3 2020 | $260,915,000 | +50.4% | 5,283,818 | -3.7% | 4.77% | +41.1% |
Q2 2020 | $173,513,000 | – | 5,489,181 | – | 3.38% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |